Comparative Pharmacology
Head-to-head clinical analysis: EMETE CON versus TIGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMETE CON versus TIGAN.
EMETE-CON vs TIGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antiemetic; dopaminergic antagonist at D2 receptors in the chemoreceptor trigger zone; also exhibits anticholinergic and antihistaminic properties.
TIGAN (trimethobenzamide) acts on the chemoreceptor trigger zone (CTZ) to inhibit emetic stimuli, primarily through antagonism of dopamine D2 receptors, though its exact mechanism is not fully elucidated.
12.5 mg intravenously over 30 seconds as a single dose; may repeat once after 1 hour if necessary.
Adults: 200 mg IM or 100 mg PO or 200 mg PR every 6–8 hours as needed.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in adults with normal renal and hepatic function; may extend to 15-20 hours in elderly or patients with hepatic impairment.
12-15 hours; may be prolonged in hepatic impairment.
Primarily hepatic metabolism (CYP2D6, CYP3A4) with <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 60-70% of metabolites, with renal elimination of metabolites constituting 25-35%.
Renal (30-50% as unchanged drug and metabolites), biliary/fecal (minor).
Category C
Category C
Antiemetic
Antiemetic